SCHEMBL15437831

SCHEMBL15437831

O=C1C(c2ccccc2)=C(c2ccccc2)C(=O)N1c1ccccc1Cl

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MGLL Q99685 1/20 0.55
▸ MEN1 O00255 2/20 0.53
▸ KMT2A Q03164 2/20 0.53
▸ RAD51 Q06609 2/20 0.49
▸ NR1H2 P55055 1/20 0.49
▸ ALDH1A1 P00352 6/20 0.47
▸ MAPT P10636 5/20 0.47
▸ HSD17B10 Q99714 3/20 0.47
▸ POLB P06746 3/20 0.47
▸ TSHR P16473 3/20 0.47
▸ L3MBTL1 Q9Y468 2/20 0.47
▸ ALOX15 P16050 1/20 0.47
▸ CASP1 P29466 1/20 0.47
▸ BCL2A1 Q16548 1/20 0.45
▸ PKM P14618 1/20 0.45
▸ PGR P06401 1/20 0.44
▸ SMN1; SMN2 Q16637 2/20 0.42
▸ NPC1 O15118 1/20 0.42
▸ RAB9A P51151 1/20 0.42
▸ BCHE P06276 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29644716 1.00 MGLL (0.55) MGLLMEN1KMT2ARAD51NR1H2
SCHEMBL15437834 0.91 RAD51 (0.60) MGLLMEN1KMT2ARAD51NR1H2
SCHEMBL15437881 0.88 MGLL (0.47) MGLLMEN1KMT2ARAD51NR1H2
SCHEMBL11211240 0.79 MGLL (0.63) MGLLMEN1KMT2ARAD51ALDH1A1
SCHEMBL2549717 0.78 MEN1 (0.73) MGLLMEN1KMT2ARAD51NR1H2
SCHEMBL16089511 0.77 MGLL (0.55) MGLLMEN1KMT2ANR1H2ALDH1A1
SCHEMBL15438306 0.77 MGLL (0.55) MGLLMEN1KMT2ANR1H2ALDH1A1
SCHEMBL1471696 0.75 MGLL (0.53) MGLLMEN1KMT2ARAD51NR1H2
SCHEMBL15437909 0.73 MEN1 (0.63) MGLLMEN1KMT2ARAD51NR1H2
SCHEMBL15438011 0.73 MAPT (0.43) MEN1KMT2ANR1H2ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9296690-B2 Method for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof METACINE, INC. (KR) 2016-03-29 — — US claimed
US-20140275203-A1 Method for Inhibiting Differentiation of Osteoclast and Pharmaceutical Composition Comprising Thereof METACINE, INC. (KR) 2014-09-18 — — US claimed
US-20140031563-A1 New compounds for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof METACINE, INC. (KR) 2014-01-30 — — US claimed
CN-114456100-A Method for preparing maleimide through cyclization of aryl acetaldehyde and primary amine 长沙资材科技有限公司 2022-05-10 — — CN disclosed
US-9296690-B2 Method for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof METACINE, INC. (KR) 2016-03-29 — — US disclosed
US-9296690-B2 Method for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof METACINE, INC. (KR) 2016-03-29 — — US disclosed
US-9296690-B2 Method for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof METACINE, INC. (KR) 2016-03-29 — — US disclosed
US-20140275203-A1 Method for Inhibiting Differentiation of Osteoclast and Pharmaceutical Composition Comprising Thereof METACINE, INC. (KR) 2014-09-18 — — US disclosed
US-20140275203-A1 Method for Inhibiting Differentiation of Osteoclast and Pharmaceutical Composition Comprising Thereof METACINE, INC. (KR) 2014-09-18 — — US disclosed
US-20140275203-A1 Method for Inhibiting Differentiation of Osteoclast and Pharmaceutical Composition Comprising Thereof METACINE, INC. (KR) 2014-09-18 — — US disclosed
US-20140031563-A1 New compounds for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof METACINE, INC. (KR) 2014-01-30 — — US disclosed
US-20140031563-A1 New compounds for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof METACINE, INC. (KR) 2014-01-30 — — US disclosed
US-20140031563-A1 New compounds for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof METACINE, INC. (KR) 2014-01-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140031563-A1 New compounds for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof SOST, MYD88, MSR1 MGLL 4191/4885MEN1 325/4885KMT2A 2720/4885
US-20140275203-A1 Method for Inhibiting Differentiation of Osteoclast and Pharmaceutical Composition Comprising Thereof SOST, MYD88, MSR1 MGLL 4069/4885MEN1 508/4885KMT2A 2691/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback